Genta's Genasense Rolling NDA For Chronic Leukemia To Wrap In Fourth Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
The company has requested an FDA meeting to discuss a confirmatory Phase IV study protocol.
You may also be interested in...
Genasense CLL Trial Meets Primary Endpoint, But Survival Benefit Not Yet Shown
Genta believes that the lack of a survival benefit seen in a Phase III trial of Genasense in chronic lymphocytic leukemia reflects the relatively short follow-up time available for analysis, CEO Raymond Warrell said during a Nov. 9 earnings call
Sanofi-Aventis Drops Genasense After Genta Declines To Modify Deal
Genta says it was approached by Aventis “on several occasions” after a negative Oncologic Drugs Advisory Committee review in May about modifying the financial terms of the oblimersen collaboration, “but we declined to make those accommodations.”
Spectrum’s Iso-Vorin Could Clear FDA For Osteosarcoma By First Quarter
The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.